期刊
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
卷 183, 期 6, 页码 788-824出版社
AMER THORACIC SOC
DOI: 10.1164/rccm.2009-040GL
关键词
idiopathic pulmonary fibrosis; usual interstitial pneumonia; evidence-based medicine; diagnosis; therapeutics
资金
- Actelion
- Coalition for Pulmonary Fibrosis
- Therapeutics
- Fibrogen
- Genzyme
- Gilead
- Nektar
- ASP/CHEST Foundation
- American Health Education
- Astra Zeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Pfizer
- Schering
- WebMD
- Bayer Schering Pharma
- Pan Pharma
- Biogen
- Novartis
- Neopharm
- Intermune
- Johnson Johnson
- Siemens
- Barilla
- World Allergy Organization
- American Thoracic Society
- European Respiratory Society
- Japanese Respiratory Society
- Latin American Thoracic Association
This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据